Agenda At A Glance
Plenary Sessions – Next Generation Innovations
Workshop A
Workshop B
Workshop C
Innovating the Future of Cell Therapy with Next Generation Gene Editing
Unlocking the Power of Cord Blood as a Platform for Scalable Manufacturing of Universal Cell Therapy Products
Navigating Through a New Complex Regulatory Landscape to Drive Future Product Development
Workshop D
Workshop E
Workshop F
Moving to the Future: Translating Product Development for an ‘Offthe- Shelf’ World Beyond Oncology
Manufacturing Challenges: Large Scale Complex Editing of Cell Therapy Products
Turning a Universal Dream into a Commercial Reality
Industry Leader’s Fireside Chat
Plenary Sessions - Spotlight on Clinical Validation
Morning Refreshment Break & Speed Networking
Pre-Clinical & Translational
Manufacturing & CMC
Supply/Storage
Advancing Donor-Derived Approaches with Enhanced Screening & Selection
Improving Scalability to Bring the True Promise of Allogeneic Products to Life
Optimizing Cryopreservation to Revolutionize the Cold Supply Chain
Refreshment Break & Networking
Novel Platforms & Cell Types for Greater Safety &
Efficacy of Response
Developing a Safe and Consistent Allogeneic Product for Commercial Readiness
Developing a Robust Supply Chain for Clinical and Commercial
Needs
Refreshment Break & Tech Slam
Advancing Safety with Innovations in Gene Editing
Utilizing Alternative Effector Cells for an Off-the-Shelf Approach
Developing a Robust Supply Chain for Clinical and Commercial
Needs
Plenary Sessions – Next Generation Innovations
Morning Refreshment Break & Poster Session
Pre-Clinical & Translational
Manufacturing & CMC
Supply/Storage
Supercharging Solid Tumor Targeting for Broader Success
Driving Automated Manufacturing & Optimizing Characterization for Successful Commercialisation of Allogenic Therapies
Revolutionizing Data Management & Integration
Refreshment Break
Plenary Sessions – Ushering in the Next Wave of Universal Cell Therapy: Future Directions
Refreshment Break
Plenary Sessions – Ushering in the Next Wave of Universal Cell Therapy: Future Directions
Advancing Durability & Persistence
Improving Persistence of Allogeneic Immune Cells for Longer Lasting Therapies
Advancing Durability to Overcome Patient Relapse Following Allogeneic Cell Therapy Treatment
Rethinking Dosing Strategies and Lymphodepletion Regimens to Optimize Persistence & Efficacy